Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.

BACKGROUND AND PURPOSE

Doxorubicin is a highly effective anticancer drug, but its clinical application is hampered by cardiotoxicity. Asymptomatic diastolic dysfunction can be the earliest manifestation of doxorubicin cardiotoxicity. Therefore, a search for therapeutic intervention that can interfere with early manifestations and possibly prevent later development of cardiotoxicity is warranted. Increased doxorubicin-dependent ROS may explain, in part, Ca and Na overload that contributes to diastolic dysfunction and development of heart failure. Therefore, we tested whether the administration of ranolazine, a selective blocker of late Na current, immediately after completing doxorubicin therapy, could affect diastolic dysfunction and interfere with the progression of functional decline.

EXPERIMENTAL APPROACH

Fischer 344 rats received a cumulative dose of doxorubicin of 15 mg·kg over a period of 2 weeks. After the assessment of diastolic dysfunction, the animals were treated with ranolazine (80 mg·kg , daily) for the following 4 weeks.

KEY RESULTS

While diastolic and systolic function progressively deteriorated in doxorubicin-treated animals, treatment with ranolazine relieved diastolic dysfunction and prevented worsening of systolic function, decreasing mortality. Ranolazine lowered myocardial NADPH oxidase 2 expression and oxidative/nitrative stress. Expression of the Na /Ca exchanger 1 and Na 1.5 channels was reduced and of the sarcoplasmic/endoplasmic reticulum Ca -ATPase 2 protein was increased. In addition, ranolazine lowered doxorubicin-induced hyper-phosphorylation and oxidation of Ca /calmodulin-dependent protein kinase II, and decreased myocardial fibrosis.

CONCLUSIONS AND IMPLICATIONS

Ranolazine, by the increased Na influx, induced by doxorubicin, altered cardiac Ca and Na handling and attenuated diastolic dysfunction induced by doxorubicin, thus preventing the progression of cardiomyopathy.

LINKED ARTICLES

This article is part of a themed section on New Insights into Cardiotoxicity Caused by Chemotherapeutic Agents. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.21/issuetoc.